ReviewInternational journal of molecular sciences2026
Exploring the Role of Extracellular Vesicles in Pancreatic and Hepatobiliary Cancers: Advances Through Artificial Intelligence.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal (GI) cancers constitute an umbrella term for a wide variety of malignancies that are located in the digestive tract (esophageal, gastric, small and large intestine, anus, liver, gallbladder, and pancreas), with 25% of total cancers and 35% of cancer-related deaths being attributed to them. An alarming trend of rising GI malignancy diagnoses, especially in younger age groups, underscores the need for discoveries in liquid-based biomarkers that facilitate both early detection and optimal disease management. Extracellular vesicles (EVs) not only constitute promising nano-sized biomarkers, but also, via bioengineering, have shown a great therapeutic potential, with artificial intelligence (AI) revolutionizing their research via the selection of the best biomarkers from omics, the recognition of pathophysiological patterns, and facilitating a faster drug-development via AI-driven EV engineering, drug delivery modeling, and target identification. In this review, we will provide a clear insight into the implementation of AI methodologies in EV-based biomarker discovery and therapeutics for pancreatic and hepatobiliary cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.